Colchicine treats several conditions beyond gout, ranging from heart disease to inflammatory skin disorders. The FDA has approved it for two non-gout uses: familial Mediterranean fever and cardiovascular risk reduction in people with established heart disease. Doctors also prescribe it off-label for pericarditis, Behçet’s disease, and a variety of inflammatory skin conditions.
Heart Disease Prevention
In 2023, the FDA approved a low-dose colchicine tablet specifically to reduce the risk of heart attack, stroke, and cardiovascular death in adults with established atherosclerotic disease or multiple risk factors. This was a major expansion of the drug’s role. In clinical trials, a daily low dose lowered rates of major cardiovascular events by 31% in people with stable coronary artery disease and by 23% in people who had recently suffered a heart attack.
The connection between colchicine and heart health comes down to inflammation. Atherosclerosis, the buildup of plaque in arteries, is driven partly by chronic inflammation in blood vessel walls. Colchicine disrupts several inflammatory pathways at the cellular level: it blocks a key inflammation sensor inside cells (the NLRP3 inflammasome), interferes with immune cell migration to inflamed tissue, and reduces platelet activation. These effects appear to slow the progression of plaque and reduce the chance of a dangerous rupture that triggers a heart attack or stroke.
Familial Mediterranean Fever
Familial Mediterranean fever (FMF) is an inherited condition that causes recurring episodes of fever, chest pain, abdominal pain, and joint swelling. Episodes typically last one to three days and can be debilitating. Colchicine is the cornerstone treatment, and it’s the only other condition besides gout for which colchicine has long held FDA approval. It works both to prevent attacks and to protect against a serious long-term complication: amyloidosis, a buildup of abnormal protein in the kidneys and other organs.
The drug is approved for adults and children four years and older. Children aged 4 to 6 typically take 0.3 to 1.8 mg daily, children 6 to 12 take 0.9 to 1.8 mg daily, and adolescents and adults take 1.2 to 2.4 mg daily. Doses can be split into one or two daily doses and adjusted gradually based on how well symptoms are controlled and whether side effects develop. Most people with FMF take colchicine for life.
Pericarditis
Pericarditis is inflammation of the thin sac surrounding the heart. It causes sharp chest pain that often worsens when lying down or breathing deeply. While a first episode usually resolves within weeks, roughly 15 to 30 percent of people experience recurrences, sometimes repeatedly over months or years. Colchicine has become a standard part of treatment for both acute and recurrent pericarditis, typically given alongside anti-inflammatory painkillers.
For a first episode, colchicine is generally used for about three months. For recurrent pericarditis, treatment extends to six to twelve months. The typical dose is 0.5 mg twice daily, though people who weigh under 70 kg, are over 70 years old, or have reduced kidney function usually take a lower dose of 0.5 mg once daily. Adding colchicine significantly cuts the rate of recurrence compared to anti-inflammatory drugs alone, which is why current guidelines recommend it as a first-line add-on therapy.
Behçet’s Disease and Oral Ulcers
Behçet’s disease is a chronic condition that causes painful ulcers in the mouth and genitals, along with eye inflammation, skin lesions, and joint pain. Colchicine is one of the most commonly prescribed treatments, particularly for the oral ulcers and joint symptoms. A recent study in children with Behçet’s spectrum disorders found that colchicine significantly reduced both the frequency and duration of oral ulcers, along with improvements in pain scores and inflammatory markers during symptom-free periods.
The drug doesn’t cure Behçet’s disease, but it can make flares less frequent and less severe. It’s generally considered a first-line option for the mucocutaneous (mouth and skin) symptoms rather than the more serious eye or blood vessel involvement, which typically requires stronger immunosuppressive therapy.
Inflammatory Skin Conditions
Dermatologists use colchicine off-label for a surprisingly long list of skin conditions, especially those driven by neutrophils, a type of white blood cell that causes tissue damage when it accumulates in the wrong place. Colchicine is particularly effective against these neutrophilic disorders because it directly interferes with the structural proteins (microtubules) that immune cells need to migrate toward inflamed tissue.
Conditions where colchicine has shown benefit include:
- Sweet’s syndrome: a classic neutrophilic disorder with tender red skin nodules and fever
- Leukocytoclastic vasculitis: inflammation of small blood vessels that causes purplish spots on the skin, particularly the legs
- Erythema nodosum: painful red bumps typically on the shins
- Palmoplantar pustulosis: a chronic condition causing pus-filled blisters on the palms and soles
- Dermatitis herpetiformis: an intensely itchy blistering rash linked to celiac disease, where patients who can’t tolerate standard treatment have responded rapidly to colchicine
- Hidradenitis suppurativa: painful, recurring abscesses in skin folds
Case reports also describe benefit in rarer conditions like epidermolysis bullosa acquisita (a blistering disease) and linear IgA disease, where one patient who hadn’t responded to conventional therapy saw complete recovery within 10 weeks on colchicine. These uses are off-label, meaning they’re based on clinical experience and smaller studies rather than large-scale trials.
Side Effects to Expect
Colchicine has a narrow therapeutic window, meaning the gap between an effective dose and a harmful one is relatively small. More than 10% of people experience gastrointestinal side effects when starting therapy, most commonly diarrhea, nausea, abdominal pain, and vomiting. These symptoms usually improve as the body adjusts or when the dose is reduced.
The bigger safety concern involves drug interactions. Colchicine is broken down by specific enzyme and transport systems in the body, and other drugs that use the same pathways can cause colchicine to accumulate to dangerous levels. Fatal interactions have been reported with clarithromycin, a common antibiotic. Other medications that require caution include the antifungal ketoconazole, the heart medication verapamil, the immune suppressant cyclosporine, and the antibiotic erythromycin. Even grapefruit juice can interfere with colchicine metabolism enough to increase the risk of serious side effects. If you take colchicine regularly, make sure every prescriber you see knows about it before adding new medications.